Development of curcumin-loaded poly(hydroxybutyrate-co-hydroxyvalerate) nanoparticles as anti-inflammatory carriers to human-activated endothelial cells
Source abstract
Abstract
Curcumin (Cm)-loaded poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) nanoparticles (CmPN) were obtained and characterized and their effect on human endothelial cells (HEC) was assessed. Different CmPN formulations have been prepared using the emulsion solvent evaporation technique, and characterized for size, structure, Zeta potential, Cm entrapment efficiency, and in vitro Cm release. CmPN cytotoxicity and cellular uptake have been followed using HEC. Also, the effect of CmPN treatment on the p38MAPK signaling pathway in endothelial cells was investigated. The results obtained by electron and atomic force microscopy revealed the spherical shape of the CmPN formulation. Based on size and encapsulation efficiency, the CmPN formulation with the average diameter of 186 nm and with the highest encapsulation efficiency (83 %) has been used in the further studies. The release of Cm from CmPN was ~18 % after 8 h of incubation at 37 °C, followed by a slow release until 144 h, when it reached 44 %, indicating a controlled release. CmPN are taken up by HEC and exhibited low cytotoxicity at concentrations up to 10 μM. The pre-treatment of HEC with CmPN before exposure to tumor necrosis factor-alpha (TNF-α) determined a decrease of p38MAPK phosphorylation. In conclusion, Cm encapsulated into PHBV nanoparticles, at concentration up to 10 μM, has low cytotoxicity and display anti-inflammatory activity on TNF-α-activated HEC by suppressing the phosphorylation of p38MAPK.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Curcumin's Biomedical Applications · Nanoparticle-Based Drug Delivery · Nuclear Receptors and Signaling
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (69)
Show source-provided references
1. Aggarwal BB, Harikumar KB (2009a) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41(1):40–59. doi: 10.1016/j.biocel.2008.06.01010.1016/j.biocel.2008.06.010 ↗
2. Aggarwal BB, Harikumar KB (2009b) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell B 41(1):40–59. doi: 10.1016/j.biocel.2008.06.01010.1016/j.biocel.2008.06.010 ↗
3. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23(1A):363–398
4. Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S, Sethi G (2007) Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol 73(7):1024–1032. doi: 10.1016/j.bcp.2006.12.01010.1016/j.bcp.2006.12.010 ↗
5. Albanese A, Tang PS, Chan WC (2012) The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16. doi: 10.1146/annurev-bioeng-071811-15012410.1146/annurev-bioeng-071811-150124 ↗
6. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4(6):807–818. doi: 10.1021/mp700113r10.1021/mp700113r ↗
7. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB (2008a) Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 267(1):133–164. doi: 10.1016/j.canlet.2008.03.02510.1016/j.canlet.2008.03.025 ↗
8. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB (2008b) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76(11):1590–1611. doi: 10.1016/j.bcp.2008.08.00810.1016/j.bcp.2008.08.008 ↗
9. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR, Aggarwal BB (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79(3):330–338. doi: 10.1016/j.bcp.2009.09.00310.1016/j.bcp.2009.09.003 ↗
10. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC (2011) Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila) 4(8):1158–1171. doi: 10.1158/1940-6207.CAPR-10-000610.1158/1940-6207.CAPR-10-0006 ↗
11. Binion DG, Otterson MF, Rafiee P (2008) Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 57(11):1509–1517. doi: 10.1136/gut.2008.15249610.1136/gut.2008.152496 ↗
12. Bruzell EM, Morisbak E, Tonnesen HH (2005) Studies on curcumin and curcuminoids. XXIX. Photoinduced cytotoxicity of curcumin in selected aqueous preparations. Photoch Photobio Sci 4(7):523–530. doi: 10.1039/B503397g10.1039/b503397g ↗
13. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21(4B):2895–2900
14. Cuenoud HF, Joris I, Langer RS, Majno G (1987) Focal arteriolar insudation. A response of arterioles to chronic nonspecific irritation. Am J Pathol 127(3):592–604
15. Das M, Sahoo SK (2012) Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS ONE 7(3):e32920. doi: 10.1371/journal.pone.003292010.1371/journal.pone.0032920 ↗
16. Edgell CJ, McDonald CC, Graham JB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 80(12):3734–373710.1073/pnas.80.12.3734 ↗
17. Errico C, Bartoli C, Chiellini F, Chiellini E (2009) Poly(hydroxyalkanoates)-based polymeric nanoparticles for drug delivery. J Biomed Biotechnol. doi: 10.1155/2009/57170210.1155/2009/571702 ↗
18. Feng R, Song Z, Zhai G (2012) Preparation and in vivo pharmacokinetics of curcumin-loaded PCL-PEG-PCL triblock copolymeric nanoparticles. Int J Nanomed 7:4089–4098. doi: 10.2147/IJN.S3360710.2147/IJN.S33607 ↗
19. Gangrade N, Price JC (1991) Poly(hydroxybutyrate-hydroxyvalerate) microspheres containing progesterone: preparation, morphology and release properties. J Microencapsul 8(2):185–202. doi: 10.3109/0265204910907148710.3109/02652049109071487 ↗
20. Gerlowski LE, Jain RK (1986) Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31(3):288–30510.1016/0026-2862(86)90018-X ↗
21. Gursel I, Hasirci V (1995) Properties and drug release behaviour of poly(3-hydroxybutyric acid) and various poly(3-hydroxybutyrate-hydroxyvalerate) copolymer microcapsules. J Microencapsul 12(2):185–193. doi: 10.3109/0265204950901528910.3109/02652049509015289 ↗
22. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95(8):4607–4612. doi: 10.1073/pnas.95.8.460710.1073/pnas.95.8.4607 ↗
23. Holpuch AS, Hummel GJ, Tong M, Seghi GA, Pei P, Ma P, Mumper RJ, Mallery SR (2010) Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm Res 27(7):1224–1236. doi: 10.1007/s11095-010-0121-y10.1007/s11095-010-0121-y ↗
24. Jiang J, Wang W, Sun YJ, Hu M, Li F, Zhu DY (2007) Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol 561(1–3):54–62. doi: 10.1016/j.ejphar.2006.12.02810.1016/j.ejphar.2006.12.028 ↗
25. Jin H, Heller DA, Sharma R, Strano MS (2009) Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano 3(1):149–158. doi: 10.1021/nn800532m10.1021/nn800532m ↗
26. Joris I, Cuenoud HF, Doern GV, Underwood JM, Majno G (1990) Capillary leakage in inflammation. A study by vascular labeling. Am J Pathol 137(6):1353–1363
27. Jurenka JS (2009) Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 14(2):141–153
28. Kim YS, Ahn Y, Hong MH, Joo SY, Kim KH, Sohn IS, Park HW, Hong YJ, Kim JH, Kim W, Jeong MH, Cho JG, Park JC, Kang JC (2007) Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol 50(1):41–49. doi: 10.1097/FJC.0b013e31805559b910.1097/FJC.0b013e31805559b9 ↗
29. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB (1998) Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 55(6):775–78310.1016/S0006-2952(97)00557-1 ↗
30. Lao CD, Ruffin M, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME, Crowell J, Rock CL, Brenner DE (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6:10. doi: 10.1186/1472-6882-6-1010.1186/1472-6882-6-10 ↗
31. Li L, Braiteh FS, Kurzrock R (2005) Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104(6):1322–1331. doi: 10.1002/cncr.2130010.1002/cncr.21300 ↗
32. Li J, Jiang Y, Wen J, Fan G, Wu Y, Zhang C (2009) A rapid and simple HPLC method for the determination of curcumin in rat plasma: assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomed Chromatogr 23(11):1201–1207. doi: 10.1002/bmc.124410.1002/bmc.1244 ↗
33. Lin SJ, Jan KM, Chien S (1990) Role of dying endothelial cells in transendothelial macromolecular transport. Arteriosclerosis 10(5):703–70910.1161/01.ATV.10.5.703 ↗
34. Lobatto ME, Fayad ZA, Silvera S, Vucic E, Calcagno C, Mani V, Dickson SD, Nicolay K, Banciu M, Schiffelers RM, Metselaar JM, van Bloois L, Wu HS, Fallon JT, Rudd JH, Fuster V, Fisher EA, Storm G, Mulder WJ (2010) Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm 7(6):2020–2029. doi: 10.1021/mp100309y10.1021/mp100309y ↗
35. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ (2011) Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 10(11):835–852. doi: 10.1038/nrd357810.1038/nrd3578 ↗
36. Manju S, Sreenivasan K (2012) Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci 368(1):144–151. doi: 10.1016/j.jcis.2011.11.02410.1016/j.jcis.2011.11.024 ↗
37. Masaeli E, Morshed M, Nasr-Esfahani MH, Sadri S, Hilderink J, van Apeldoorn A, van Blitterswijk CA, Moroni L (2013) Fabrication, characterization and cellular compatibility of poly(hydroxy alkanoate) composite nanofibrous scaffolds for nerve tissue engineering. PLoS ONE 8(2):e57157. doi: 10.1371/journal.pone.005715710.1371/journal.pone.0057157 ↗
38. Mendes JB, Riekes MK, de Oliveira VM, Michel MD, Stulzer HK, Khalil NM, Zawadzki SF, Mainardes RM, Farago PV (2012) PHBV/PCL microparticles for controlled release of resveratrol: physicochemical characterization, antioxidant potential, and effect on hemolysis of human erythrocytes. ScientificWorldJournal 2012:542937. doi: 10.1100/2012/54293710.1100/2012/542937 ↗
39. Menon VP, Sudheer AR (2007) Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105–125. doi: 10.1007/978-0-387-46401-5_310.1007/978-0-387-46401-5_3 ↗
40. Mo L, Hou L, Guo D, Xiao X, Mao P, Yang X (2012) Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells. Int J Pharm. doi: 10.1016/j.ijpharm.2012.07.050
41. Mohanty C, Sahoo SK (2010) The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 31(25):6597–6611. doi: 10.1016/j.biomaterials.2010.04.06210.1016/j.biomaterials.2010.04.062 ↗
42. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1–2):55–6310.1016/0022-1759(83)90303-4 ↗
43. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR (2012) ApoE3 mediated polymeric nanoparticles containing curcumin: apoptosis induced in vitro anticancer activity against neuroblastoma cells. Int J Pharm 437(1–2):29–41. doi: 10.1016/j.ijpharm.2012.07.06210.1016/j.ijpharm.2012.07.062 ↗
44. Pignatello R, Musumeci T, Impallomeni G, Carnemolla GM, Puglisi G, Ballistreri A (2009) Poly(3-hydroxybutyrate-co-epsilon-caprolactone) copolymers and poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-epsilon-caprolactone) terpolymers as novel materials for colloidal drug delivery systems. Eur J Pharm Sci 37(3–4):451–46210.1016/j.ejps.2009.03.017 ↗
45. Pirvulescu MM, Gan AM, Stan D, Simion V, Calin M, Butoi E, Tirgoviste CI, Manduteanu I (2011) Curcumin and a Morus alba extract reduce pro-inflammatory effects of resistin in human endothelial cells. Phytother Res 25(12):1737–1742. doi: 10.1002/ptr.346310.1002/ptr.3463 ↗
46. Ramaswami G, Chai H, Yao Q, Lin PH, Lumsden AB, Chen C (2004) Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg 40(6):1216–1222. doi: 10.1016/j.jvs.2004.09.02110.1016/j.jvs.2004.09.021 ↗
47. Ranjan AP, Mukerjee A, Helson L, Vishwanatha JK (2012) Scale up, optimization and stability analysis of Curcumin C3 complex-loaded nanoparticles for cancer therapy. J Nanobiotechnol 10:38. doi: 10.1186/1477-3155-10-3810.1186/1477-3155-10-38 ↗
48. Rejinold NS, Muthunarayanan M, Divyarani VV, Sreerekha PR, Chennazhi KP, Nair SV, Tamura H, Jayakumar R (2011) Curcumin-loaded biocompatible thermoresponsive polymeric nanoparticles for cancer drug delivery. J Colloid Interface Sci 360(1):39–51. doi: 10.1016/j.jcis.2011.04.00610.1016/j.jcis.2011.04.006 ↗
49. Reusch RN (2000) Transmembrane ion transport by polyphosphate/poly-(R)-3-hydroxybutyrate complexes. Biochemistry (Mosc) 65(3):280–295
50. Rogers NM, Stephenson MD, Kitching AR, Horowitz JD, Coates PT (2012) Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells. Br J Pharmacol 166(1):194–209. doi: 10.1111/j.1476-5381.2011.01590.x10.1111/j.1476-5381.2011.01590.x ↗
51. Rosca ID, Watari F, Uo M (2004) Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J Control Release 99(2):271–280. doi: 10.1016/j.jconrel.2004.07.00710.1016/j.jconrel.2004.07.007 ↗
52. Sevastianov VI, Perova NV, Shishatskaya EI, Kalacheva GS, Volova TG (2003) Production of purified polyhydroxyalkanoates (PHAs) for applications in contact with blood. J Biomater Sci Polym Ed 14(10):1029–104210.1163/156856203769231547 ↗
53. Siflinger-Birnboim A, Del Vecchio PJ, Cooper JA, Blumenstock FA, Shepard JM, Malik AB (1987) Molecular sieving characteristics of the cultured endothelial monolayer. J Cell Physiol 132(1):111–117. doi: 10.1002/jcp.104132011510.1002/jcp.1041320115 ↗
54. Singh S, Khar A (2006) Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 6(3):259–27010.2174/187152006776930918 ↗
55. Stemerman MB (1981) Effects of moderate hypercholesterolemia on rabbit endothelium. Arteriosclerosis 1(1):25–3210.1161/01.ATV.1.1.25 ↗
56. Sultana N, Wang M (2012) PHBV/PLLA-based composite scaffolds fabricated using an emulsion freezing/freeze-drying technique for bone tissue engineering: surface modification and in vitro biological evaluation. Biofabrication 4(1):015003. doi: 10.1088/1758-5082/4/1/01500310.1088/1758-5082/4/1/015003 ↗
57. Thomas CM, Lutz JF (2011) Precision synthesis of biodegradable polymers. Angew Chem Int Ed Engl 50(40):9244–9246. doi: 10.1002/anie.20110307610.1002/anie.201103076 ↗
58. Trewyn BG, Nieweg JA, Zhao Y, Lin VSY (2008) Biocompatible mesoporous silica nanoparticles with different morphologies for animal cell membrane, penetration. Chem Eng J 137(1):23–29. doi: 10.1016/j.cej.2007.09.04510.1016/j.cej.2007.09.045 ↗
59. van Hinsbergh VW (1997) Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. Arterioscler Thromb Vasc Biol 17(6):1018–102310.1161/01.ATV.17.6.1018 ↗
60. Verlinden RA, Hill DJ, Kenward MA, Williams CD, Radecka I (2007) Bacterial synthesis of biodegradable polyhydroxyalkanoates. J Appl Microbiol 102(6):1437–1449. doi: 10.1111/j.1365-2672.2007.03335.x10.1111/j.1365-2672.2007.03335.x ↗
61. Vilos C, Velasquez LA (2012) Therapeutic strategies based on polymeric microparticles. J Biomed Biotechnol 2012:672760. doi: 10.1155/2012/67276010.1155/2012/672760 ↗
62. Wan S, Sun Y, Sun L, Tan F (2012) Chitosan microparticles for oral bioavailability improvement of the hydrophobic drug curcumin. Pharmazie 67(6):525–528
63. Wang J, Dong SJ (2012) ICAM-1 and IL-8 are expressed by DEHP and suppressed by curcumin through ERK and p38MAPK in human umbilical vein endothelial cells. Inflammation 35(3):859–870. doi: 10.1007/s10753-011-9387-410.1007/s10753-011-9387-4 ↗
64. Wiggam MI, O’Kane MJ, Harper R, Atkinson AB, Hadden DR, Trimble ER, Bell PM (1997) Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. A randomized controlled study. Diabetes Care 20(9):1347–135210.2337/diacare.20.9.1347 ↗
65. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC (2010) Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 351(1):19–29. doi: 10.1016/j.jcis.2010.05.02210.1016/j.jcis.2010.05.022 ↗
66. Yallapu MM, Othman SF, Curtis ET, Bauer NA, Chauhan N, Kumar D, Jaggi M, Chauhan SC (2012) Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine 7:1761–1779. doi: 10.2147/IJN.S29290
67. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK (1995) Vascular-permeability in a human tumor xenograft—molecular-size dependence and cutoff size. Cancer Res 55(17):3752–3756
68. Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z (2010) Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm 76(1):10–16. doi: 10.1016/j.ejpb.2010.05.00510.1016/j.ejpb.2010.05.005 ↗
69. Zhao JF, Ching LC, Huang YC, Chen CY, Chiang AN, Kou YR, Shyue SK, Lee TS (2012) Molecular mechanism of curcumin on the suppression of cholesterol accumulation in macrophage foam cells and atherosclerosis. Mol Nutr Food Res 56(5):691–701. doi: 10.1002/mnfr.20110073510.1002/mnfr.201100735 ↗